Utility of NGS Assays for the Evaluation of Lymphoid Malignancies – Webinar
This webinar will explore how insights gained through NGS translate to the development of improved treatment of lymphoid malignancies.
25Feb
News
16Oct
Invivoscribe Leukaemia and Lymphoma Molecular Diagnostics Seminar – Register Now
Registration is now open for the Invivoscribe Leukaemia and Lymphoma Molecular Diagnostics Seminar.
19Sep
Invivoscribe MRD controls NOW AVAILABLE
Abacus dx is pleased to announce the launch of the new LymphoTrack B-cell Low Positive Controls and LymphoQuant B-cell Internal Controls as part of Invivoscribe’s MRD B-Cell Bundled Solution.
24Jan
Invivoscribe LymphoTrack Dx IVD Assays now available
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
11May
Join Invivoscribe at EHA 2018
Planning on attending EHA 2018 in Sweden?
Invivoscribe invites to you attend a dinner social. Hear about ‘Minimal Residual Disease in Multiple Myeloma by NGS: A Comparison with Flow Cytometry’.
24Feb
New Products from Invivoscribe
Minimal Residual Disease (MRD) testing by Next Generation Sequencing (NGS) has become an important methodology demonstrating clear potential to optimize therapeutic management of lymphoproliferative diseases.
26Nov
Visit Invivoscribe at the 2015 ASH Annual Meeting
Visit Invivoscribe at Booth #324 at the American Society of Haematology (ASH) Meeting for information regarding NGS assays and their application for clonality testing, somatic hypermutation testing, and Minimal Residual Disease (MRD).